Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …

Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and
programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy …

PURPOSE The combination of talimogene laherparepvec (T-VEC) and pembrolizumab
previously demonstrated an acceptable safety profile and an encouraging complete …

Pancreatic ductal adenocarcinoma (PDAC) remains a lethal malignancy with an
immunosuppressive microenvironment that is resistant to most therapies. IL17 is involved in …

Importance Hyperprogressive disease (HPD) is a new pattern of progression recently
described in patients with cancer treated with programmed cell death 1 (PD-1) and …

Purpose Genetic alterations causing overexpression of programmed death-1 ligands are
near universal in classic Hodgkin lymphoma (cHL). Nivolumab, a programmed death-1 …

Novel patterns of response and progression to immunotherapy have been reported that are
not observed with conventional cytotoxic or targeted anticancer treatments. A major …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous
melanoma have been significantly revised over the past few years in response to emerging …

Importance This analysis provides long-term follow-up in patients withBRAFwild-type
advanced melanoma receiving first-line therapy based on anti–programmed cell death 1 …

Melanoma is among the most sensitive of malignancies to immune modulation. Although
multiple trials conducted over decades with vaccines, cytokines, and cell therapies …